Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yang, Yunpeng; Wang, Zhehai; Fang, Jian; Yu, Qitao; Han, Baohui; Cang, Shundong; Chen, Gongyan; Mei, Xiaodong; Yang, Zhixiong; Ma, Rui; Bi, Minghong; Ren, Xiubao; Zhou, Jianying; Li, Baolan; Song, Yong; Feng, Jifeng; Li, Juan; He, Zhiyong; Zhou, Rui; Li, Weimin; Lü, You; Wang, Yingyi; Wang, Lijun; Yang, Nong; Zhang, Yan; Yu, Zhuang; Zhao, Yanqiu; Xie, Conghua; Cheng, Ying; Zhou, Hui; Wang, Shuyan; Zhu, Donglei; Zhang, Wen; Zhang, Li

doi:10.1016/j.jtho.2020.07.014

Public

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Published in Journal of Thoracic Oncology • Aug 8, 2020

Authors:

Yunpeng Yang

Zhehai Wang

Jian Fang

Abstract

INTRODUCTION: Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the efficacy and safety of sintilimab with placebo, both in combina...

Subject

Medicine

Pemetrexed

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!